- RecruitingTherapeutic exploratory (Phase II)
MYOCIT - Baricitinib in the treatment of new-onset juvenile dermatomyositis: a phase II trial
This study, called MYOCIT, is looking at a medicine called baricitinib for young people with a new diagnosis of juvenile dermatomyositis. It's a Phase II trial, meaning doctors want to see how well it works and if it's safe. They'll measure improvements in symptoms like muscle strength and skin rashes.
For: Juvenile DermatomyositisFrance - RecruitingTherapeutic confirmatory (Phase III)
I4V-MC-KHAB: A Multicenter, Open-Label, Pharmacokinetic and Safety Study of Baricitinib in Pediatric Patients From 1 Year to Less Than 18 Years Old Hospitalized With COVID-19
This study is looking at a medicine called Baricitinib for children aged 1 to 18 who are in hospital with COVID-19. We want to see how the body handles the medicine and if it's safe for them. This is a later stage of testing to confirm its effects.
For: Covid19 · Corona Virus InfectionBelgium · Spain - Active not recruitingPHASE3
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
This study is looking at a new medicine called baricitinib for children aged 1 to 17 with a type of arthritis called systemic juvenile idiopathic arthritis (sJIA). It aims to see if baricitinib is safe and helps to reduce their symptoms.
For: Systemic Juvenile Idiopathic ArthritisArgentina · Belgium · Brazil - RecruitingPHASE3
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
This study looks at a medicine called baricitinib for children aged 1 to 17 with Juvenile Idiopathic Arthritis (JIA). It checks if the medicine is safe and helps treat their JIA. Participants have been in previous baricitinib studies for JIA.
For: Juvenile Idiopathic ArthritisArgentina · Australia · Austria - RecruitingTherapeutic confirmatory (Phase III)
I4V-MC-JAIP: A Phase 3, Multicenter, Randomized, Double blind, Placebo controlled, Parallel group, Outpatient Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Baricitinib in Pediatric Patients with Moderate-to-Severe Atopic Dermatitis
This study is looking at a new medicine called Baricitinib for children and teenagers with moderate to severe eczema. It wants to see if the medicine is safe and effective in helping their skin get better, compared to a dummy pill.
For: Atopic DermatitisHungary · Czechia · Poland - RecruitingPHASE3
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
This study investigates if a drug called baricitinib can protect the body's insulin-making cells in children and adults newly diagnosed with type 1 diabetes. It aims to see if preserving these cells helps manage the condition better.
For: Diabetes Mellitus, Type 1United States · Australia · Belgium - Recruiting
Molecular Signatures in Inflammatory Skin Disease
This study looks at people with skin conditions like eczema and psoriasis to understand how their bodies respond to new treatments. We want to find patterns in their genes and cells to help doctors choose the best medicine for each person in the future.
For: Atopic Dermatitis · PsoriasisGermany - RecruitingPHASE3
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
This study is looking at a medicine called baricitinib for children aged 6 to 17 with severe alopecia areata, a condition causing hair loss. It aims to see if the medicine is safe and helps hair grow back. The study will compare baricitinib to a dummy medicine.
For: Areata Alopecia · Alopecia · HypotrichosisUnited States · Argentina · Australia - RecruitingPHASE3
Baricitinib in Patients With Relapsing or naïve Dermatomyositis
This study is testing a new medicine called baricitinib for dermatomyositis, a rare muscle and skin condition. It aims to see if baricitinib, alongside usual care, can help lessen symptoms and reduce the need for strong steroids in adult patients.
For: DermatomyositisFrance - RecruitingPHASE3
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
This study is looking into whether a medicine called baricitinib can delay Type 1 Diabetes in children and adults who are at a high risk of developing it. It's a key step in preventing the condition.
For: Diabetes Mellitus, Type 1United States · Australia · Belgium - RecruitingPHASE3
Randomised Evaluation of COVID-19 Therapy
The RECOVERY trial looks at treatments for serious lung infections like pneumonia, including COVID-19. It helps doctors find the best ways to help hospitalised patients get better and reduce their risk of dying. Many treatments have been tested, and some have been found to be very helpful.
For: PneumoniaBelgium · Estonia · France - Active not recruitingPHASE3
A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
This study is looking at a new medicine called baricitinib for children and young people aged 2 to 17 who have a specific eye condition called uveitis. We want to see if it's safe and helps reduce eye inflammation, especially for those who haven't responded well to other treatments.
For: UveitisFrance · Germany · Italy - RecruitingPHASE3
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
This study, called REMAP-CAP, looks at different treatments for serious lung infections like pneumonia, flu, and COVID-19 in adults needing intensive care. It aims to find out which treatments work best to help patients recover.
For: Community-acquired Pneumonia, Influenza, COVID-19United States · Australia · Belgium - Active not recruitingPHASE3
A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis
This study is testing a new medicine, baricitinib, for children and teenagers aged 2 to 17 with moderate to severe eczema. Researchers want to see if it's safe and helps improve their skin compared to a dummy pill or usual treatments.
For: Atopic DermatitisArgentina · Australia · Austria